Japan Approves Shionogi Allergy Drug For Helping Unborns Breathe
This article was originally published in PharmAsia News
Japan's health ministry agreed to cover Shionogi's betamethasone under the nation's health-insurance system. The drug has been sold in Japan since the 1960s, but only for treatment of allergies. The newly approved indication is for unborn babies to help them breathe. The approval marks the first in Japan for a treatment aimed at the not-yet-born. Shionogi markets the drug in Japan as Rinderon. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.